[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CellCentric Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100367769","phase-1-study-to-evaluate-ccs1477-inobrodib-in-haematological-malignancies-100367769",false,"NCT04068597","Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","An Open-label Phase I\u002FIIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.","Inclusion Criteria:\n\n* Provision of consent\n* ECOG performance status 0-2\n* Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)\n* Must have previously received standard therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment\n* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment\n* Patients should discontinue statins prior to starting study treatment\n* CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Any unresolved reversible toxicities from prior therapy \\>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)\n* Any evidence of severe or uncontrolled systemic diseases\n* Any known uncontrolled inter-current illness\n* QTcF prolongation (\\> 470 msec)","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","A Phase 1\u002F2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.",[27,28,29,30,31,32],"Haematological Malignancy","Acute Myeloid Leukemia","Non Hodgkin Lymphoma","Multiple Myeloma","Higher-risk Myelodysplastic Syndrome","Peripheral T Cell Lymphoma","RECRUITING","2026-06-19",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2019-08-09",{"date":41,"type":20},"2027-03-31",{"name":43,"class":44},"CellCentric Ltd.","INDUSTRY",39,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100600383","phase-2-inobrodib-pomalidomide-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma-100600383","NCT07096778","Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","DoMMino-1","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy\n* Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate hematological, renal and hepatic function\n* Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners\n\nExclusion Criteria:\n\n* Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days\n* Prior treatment with p300\u002FCBP bromodomain inhibitors\n* Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)\n* Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment\n* Major surgery within 4 weeks of the first dose of study treatment\n* Live vaccine within 4 weeks of study treatment\n* Active or unresolved adverse events\n* Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma\n* Female patients who are pregnant or breast-feeding at any time during the study\n* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data",{"count":55,"type":20},100,[24],"The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.",[59,60],"Multiple Myeloma Refractory","Multiple Myeloma in Relapse",[62,63,64,65,66,67],"Inobrodib","Pomalidomide","Pomalyst","Imnovid","Dexamethasone","p300-CBP Transcription Factors","2026-05-29",{"date":70,"type":37},"2026-06-02",{"date":72,"type":37},"2026-01-22",{"date":74,"type":20},"2029-12-01",{"name":43,"class":44},20,""]